The AML cells “energy map” (based on OCR and ECAR) clearly demonstrated a shift in energy status from energetic to glycolytic (for tasquinimod) or quiescent (for S100A9-siRNA) after 48 h of therapy (Supplemental Fig. 8). Here, S100A9 is linked to acute myeloid leukemia.